SCHEMBL273686

SCHEMBL273686

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1cccc(F)c1)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
OPRK1 P41145 1/20 0.51
NPC1 O15118 8/20 0.51
RAB9A P51151 7/20 0.51
GAA P10253 3/20 0.50
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 2/20 0.48
AMY1A P0DUB6 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 2/20 0.47
GRM5 P41594 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
NFKB1 P19838 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268120 1.00 MEN1 (0.51) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL273703 0.91 MAPT (0.59) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL266718 0.91 MAPT (0.59) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL273711 0.89 NPC1 (0.58) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL266482 0.89 NPC1 (0.58) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL273713 0.89 MAPT (0.54) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL268762 0.89 MAPT (0.54) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL268992 0.88 RAB9A (0.57) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL274137 0.88 RAB9A (0.57) MEN1KMT2AOPRK1NPC1RAB9A
SCHEMBL269054 0.86 CYP2D6 (0.55) MEN1KMT2ANPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MEN1 1638/4885KMT2A 4603/4885OPRK1 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.